These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 9819036)

  • 1. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ; Hanley JP; Ludlam CA
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home treatment with recombinant activated factor VII: results from one centre.
    Ingerslev J; Thykjaer H; Kudsk Jensen O; Fredberg U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S107-10. PubMed ID: 9819039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
    Lusher JM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
    Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
    Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
    Majumdar G; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
    Nicolaisen EM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
    Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
    Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences with continuous infusion of recombinant activated factor VII.
    Schulman S; d'Oiron R; Martinowitz U; Pasi J; Briquel ME; Mauser-Bunschoten E; Morfini M; Ritchie B; Goudemand J; Lloyd J; McPherson J; Négrier C; Peerlinck K; Petrini P; Tusell J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S97-101. PubMed ID: 9819037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
    Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
    Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.